SynthesisEye (London, England)2024
Global estimates on the number of people blind or visually impaired by age-related macular degeneration: a meta-analysis from 2000 to 2020.
Synthesis in Eye (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Trends and disparities of vision impairment in Mexico from 1990 to 2023: a comparative analysis with Latin America and the Caribbean based on the Global Burden of Disease Study 2023.Lancet regional health. Americas · 2026Article
- From Trials to Treatment: Current Evidence Supporting Faricimab Use in nAMD and DME.Journal of clinical medicine · 2026Review
- The Eight-Chop Technique in Nonagenarian Patients: Real-World Intraoperative and Postoperative Outcomes.Journal of clinical medicine · 2026Article
- Real-World Persistence with Anti-VEGF Therapy in Neovascular Age-related Macular Degeneration.Ophthalmology and therapy · 2026Article
- Prevalence of macular disorders assessed by OCT in adults 45 years and older from Parintins - the Brazilian Amazon Region Eye Survey (BARES).International journal of retina and vitreous · 2026Article
- Patient Preferences for the PRIMA Retinal Prosthesis for Vision Restoration for Dry Age-Related Macular Degeneration: An International Survey Study.Translational vision science & technology · 2026Article
- The Royal College of Ophthalmologists National Ophthalmology Database age-related macular degeneration (AMD) audit: report 1, associations with socio-economic deprivation in neovascular AMD.Eye (London, England) · 2026Article
- Advances in Gene Therapy for Age-Related Macular Degeneration: A Narrative Review.Journal of clinical medicine · 2026Review
- The population characteristics and prevalence of visual impairment in a Southern European population.European journal of ophthalmology · 2026Article
- Tobacco-Attributable Age-Related Macular Degeneration Vision Impairment in Japan: A National and Prefecture-Level Analysis From 1990 to 2040.Translational vision science & technology · 2026Article
- Article
- Global burden and cross-country inequalities of age-related eye diseases from 1990 to 2021: a comprehensive analysis of temporal trends and socioeconomic disparities.Eye and vision (London, England) · 2026Article
- Levodopa Suppresses Choroidal Neovascularization Through a Tyrosinase-Dependent Dual Mechanism.Investigative ophthalmology & visual science · 2026Article
- Metabolic vulnerability, genetic susceptibility, and incident age-related eye diseases: a prospective cohort study.Frontiers in nutrition · 2026Article
- Decoding the Bone-Eye Axis: Machine Learning for Age-Related Macular Degeneration Risk Prediction.Cyborg and bionic systems (Washington, D.C.) · 2026Article
- Fibrotic scarring prevents optic nerve regeneration despite preserved axonal growth potential in adult killifish.Frontiers in neuroscience · 2026Article
- Prevalence, incidence and risk factors of visual disability in patients with exudative age-related macular degeneration: a nationwide population-based study in Korea.Frontiers in medicine · 2026Article
- A new perspective on AMD pathogenesis: a sequential Factor H-centered view of complement dysregulation.Frontiers in immunology · 2026Review
- Proteomic Insights into the Retinal Response to PRGF in a Mouse Model of Age-Related Macular Degeneration.Medicina (Kaunas, Lithuania) · 2025Article
- Nanobody-based gene therapy targeting complement component C3 reduces choroidal neovascularization in mice.Molecular therapy. Methods & clinical development · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe aimed to update estimates of global vision loss due to age-related macular degeneration (AMD).
methodsWe did a systematic review and meta-analysis of population-based surveys of eye diseases from January, 1980, to October, 2018. We fitted hierarchical models to estimate the prevalence of moderate and severe vision impairment (MSVI; presenting visual acuity from <6/18 to 3/60) and blindness ( < 3/60) caused by AMD, stratified by age, region, and year.
resultsIn 2020, 1.85 million (95%UI: 1.35 to 2.43 million) people were estimated to be blind due to AMD, and another 6.23 million (95%UI: 5.04 to 7.58) with MSVI globally. High-income countries had the highest number of individuals with AMD-related blindness (0.60 million people; 0.46 to 0.77). The crude prevalence of AMD-related blindness in 2020 (among those aged ≥ 50 years) was 0.10% (0.07 to 0.12) globally, and the region with the highest prevalence of AMD-related blindness was North Africa/Middle East (0.22%; 0.16 to 0.30). Age-standardized prevalence (using the GBD 2019 data) of AMD-related MSVI in people aged ≥ 50 years in 2020 was 0.34% (0.27 to 0.41) globally, and the region with the highest prevalence of AMD-related MSVI was also North Africa/Middle East (0.55%; 0.44 to 0.68). From 2000 to 2020, the estimated crude prevalence of AMD-related blindness decreased globally by 19.29%, while the prevalence of MSVI increased by 10.08%.
conclusionsThe estimated increase in the number of individuals with AMD-related blindness and MSVI globally urges the creation of novel treatment modalities and the expansion of rehabilitation services.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.